Abiopharma

🔍 Chaya Eri (Executive)

Company: RH (RH)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 11,000 shares of Common Stock at $39.42 per share (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,000.00 | transaction_form_type: 4
• Sold 1,100 shares of Common Stock at $135.2726 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 9,900.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,000 shares of Common Stock at $135.931 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,900.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,600 shares of Common Stock at $137.0438 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,300.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,678 shares of Common Stock at $138.2123 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,622.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,922 shares of Common Stock at $139.3763 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,700.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,700 shares of Common Stock at $140.0203 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 23,643.00 | Footnotes: F8
• Sold 11,000 shares of Stock Option (Right to Buy) at $39.42 per share (Derivative)
  Date: 2026-03-31 | Code: M | Expires: 2026-05-03 | equity_swap_involved: 0 | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F9

Footnotes:

• F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 7, 2024.
• F2: This transaction was executed in multiple trades ranging from $134.58 to $135.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F3: This transaction was executed in multiple trades ranging from $135.58 to $136.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F4: This transaction was executed in multiple trades ranging from $136.65 to $137.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F5: This transaction was executed in multiple trades ranging from $137.72 to $138.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F6: This transaction was executed in multiple trades ranging from $138.75 to $139.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F7: This transaction was executed in multiple trades ranging from $139.75 to $140.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
• F8: Held by the Chaya-Smith Revocable Trust.
• F9: This option award is fully vested and exercisable.
• REMARKS: President, Co-Chief Creative and Merchandising Officer and Director